Induzione farmacologica della sintesi emoglobinica fetale

Terapia con idrossiurea (idrossicarbamide)

Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia. (apre una nuova finestra)

Ansari SH, Shamsi TS, Ashraf M, Perveen K, Farzana T, Bohray M, Erum S, Mehboob T.

Fonte‎: J Pediatr Hematol Oncol 2011;33(5):339-43.

Hydroxyurea treatment in β-thalassemia patients: to respond or not to respond? (apre una nuova finestra)

Banan M.

Fonte‎: Ann Hematol 2013;92(3):289-99.

Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. (apre una nuova finestra)

Bradai M, Pissard S, Abad MT, Dechartres A, Ribeil JA, Landais P, de Montalembert M.

Fonte‎: Transfusion 2007;47(10):1830-6.

Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in beta-thalassemia/hemoglobin E disease. (apre una nuova finestra)

Fucharoen S, Siritanaratkul N, Winichagoon P, Chowthaworn J, Siriboon W, Muangsup W, Chaicharoen S, Poolsup N, Chindavijak B, Pootrakul P, Piankijagum A, Schechter AN, Rodgers GP.

Fonte‎: Blood 1996;87(3):887-92.

Hydroxyurea can reduce or eliminate transfusion requirements in children with major and intermediate thalassemia. (apre una nuova finestra)

Hashemi A, Abrishamkar M, Jenabzade AR, Eslami Z.

Fonte‎: Iran J Blood Cancer 2009;1(4):147-50.

Hydroxyurea as a first-line treatment of extramedullary hematopoiesis in patients with beta thalassemia: Four case reports. (apre una nuova finestra)

Karimi M, Cohan N, Pishdad P.

Fonte‎: Hematology 2015;20(1):53-7.

Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran. (apre una nuova finestra)

Karimi M, Haghpanah S, Farhadi A, Yavarian M.

Fonte‎: Int J Hematol 2012;95(1):51-6.

Report on Patients with Non Transfusion-Dependent β-Thalassemia Major Being Treated with Hydroxyurea Attending the Thalassemia Research Center, Sari, Mazandaran Province, Islamic Republic of Iran in 2013. (apre una nuova finestra)

Kosaryan M, Karami H, Zafari M, Yaghobi N.

Fonte‎: Hemoglobin 2014;38(2):115-8.

Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia. (apre una nuova finestra)

Musallam KM, Taher AT, Cappellini MD, Sankaran VG.

Fonte‎: Blood 2013;121(12):2199-212.

A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia. (apre una nuova finestra)

Yasara N, Wickramarathne N, Mettananda C, Silva I, Hameed N, Attanayaka K, Rodrigo R, Wickramasinghe N, Perera L, Manamperi A, Premawardhena A, Mettananda S

Fonte‎: Sci Rep. 2022;12(1):2752.

Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. (apre una nuova finestra)

Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC.

Fonte‎: Haematologica 2004;89(10):1172-8.

Hydroxyurea therapy in 49 patients with major beta-thalassemia. (apre una nuova finestra)

Zamani F, Shakeri R, Eslami SM, Razavi SM, Basi A.

Fonte‎: Arch Iran Med 2009;12(3):295-7.

Eritropoietina ricombinante (da sola o in combinazione con altri farmaci)

Preliminary results with administration of recombinant human erythropoietin in sickle cell/beta-thalassemia patients during pregnancy. (apre una nuova finestra)

Bourantas K, Makrydimas G, Georgiou J, Tsiara S, Lolis D.

Fonte‎: Eur J Haematol 1996;56(5):326-8.

Induction of fetal hemoglobin synthesis with recombinant human erythropoietin in anemic patients with heterozygous beta-thalassemia during pregnancy. (apre una nuova finestra)

Breymann C, Fibach E, Visca E, Huettner C, Huch A, Huch R.

Fonte‎: J Matern Fetal Med 1999;8(1):1-7.

Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules. (apre una nuova finestra)

Chaidos A, Makis A, Hatzimichael E, Tsiara S, Gouva M, Tzouvara E, Bourantas KL.

Fonte‎: Acta Haematol 2004;111(4):189-95.

Recombinant human erythropoietin therapy in a transfusion-dependent β-thalassemia major patient. (apre una nuova finestra)

Makis AC, Chaliasos N, Hatzimichael EC, Bourantas KL.

Fonte‎: Ann Hematol 2001;80(8):492-5.

Fetal globin induction--can it cure beta thalassemia? (apre una nuova finestra)

Perrine SP.

Fonte‎: Hematology Am Soc Hematol Educ Program 2005:38-44.

Medical Information for Clinicians

Induzione farmacologica della sintesi emoglobinica fetale

Terapia con idrossiurea (idrossicarbamide)

Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia. (apre una nuova finestra)

Hydroxyurea treatment in β-thalassemia patients: to respond or not to respond? (apre una nuova finestra)

Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. (apre una nuova finestra)

Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in beta-thalassemia/hemoglobin E disease. (apre una nuova finestra)

Hydroxyurea can reduce or eliminate transfusion requirements in children with major and intermediate thalassemia. (apre una nuova finestra)

Hydroxyurea as a first-line treatment of extramedullary hematopoiesis in patients with beta thalassemia: Four case reports. (apre una nuova finestra)

Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran. (apre una nuova finestra)

Report on Patients with Non Transfusion-Dependent β-Thalassemia Major Being Treated with Hydroxyurea Attending the Thalassemia Research Center, Sari, Mazandaran Province, Islamic Republic of Iran in 2013. (apre una nuova finestra)

Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia. (apre una nuova finestra)

A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia. (apre una nuova finestra)

Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. (apre una nuova finestra)

Hydroxyurea therapy in 49 patients with major beta-thalassemia. (apre una nuova finestra)

Eritropoietina ricombinante (da sola o in combinazione con altri farmaci)

Preliminary results with administration of recombinant human erythropoietin in sickle cell/beta-thalassemia patients during pregnancy. (apre una nuova finestra)

Induction of fetal hemoglobin synthesis with recombinant human erythropoietin in anemic patients with heterozygous beta-thalassemia during pregnancy. (apre una nuova finestra)

Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules. (apre una nuova finestra)

Recombinant human erythropoietin therapy in a transfusion-dependent β-thalassemia major patient. (apre una nuova finestra)

Fetal globin induction--can it cure beta thalassemia? (apre una nuova finestra)

Comitati di assistenza sanitaria (CAS)

Materiale informativo per il personale medico

Video

Induzione farmacologica della sintesi emoglobinica fetale

Terapia con idrossiurea (idrossicarbamide)

Eritropoietina ricombinante (da sola o in combinazione con altri farmaci)

Seleziona la tua lingua